Impact of GLP-1 Receptor Agonists on Bone Metabolism
Clicks: 2
ID: 324202
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
2 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #98 of 359 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 359 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
10
SUSD
one-off · no wallet required
Abstract
CONTEXT: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat type 2 diabetes mellitus (T2DM) and obesity, have shown multi-organ benefits. However, their effects on bone are uncertain. GLP-1RAs may favor skeletal health through improved metabolic control, but substantial weight loss may increase bone loss and fracture risk. Understanding this balance between benefit and risk is an important clinical priority. EVIDENCE ACQUISITION: This mini-review summarizes the current evidence on the effects of GLP-1RAs on bone health and skeletal metabolism in individuals with type 2 diabetes and obesity, as informed by a literature search using the PubMed and Embase databases. EVIDENCE SYNTHESIS: Preclinical data generally support a beneficial role for GLP-1 signaling in bone, with evidence for enhanced osteoblast activity, reduced bone resorption, and improved bone mass and strength. In people with T2DM, GLP-1RAs appear neutral to modestly beneficial for BMD and bone remodeling. In those without T2DM, greater weight loss is more consistently associated with declines in BMD and increases in bone turnover. However, clinical studies to date have had relatively short follow-up and limited focus on skeletal endpoints. Additionally, newer agents associated with greater weight loss are underrepresented in the data. CONCLUSION: Current evidence suggests that GLP-1RAs may directly benefit bone health, but these benefits may be offset by weight-loss-related skeletal risks, particularly in nondiabetic and high-risk individuals. Additional research is needed to define their true impact on bone depending on clinical context. These findings will guide strategies that preserve skeletal health while maintaining GLP-1 RAs' metabolic benefits.
| Reference Key |
openalex_W7197015820
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Vidhu Vadini, Daisy Duan, Kendall F. Moseley |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag323
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.